"id:ID","studyInvestigationalInterventions","documentVersion","label","studyDesignRationale","bcCategories","studyEstimands","name","description","uuid","id"
"820","[]","","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","[]","[]","Study Design 1","The main design for the study","0de35cdf-c347-41ab-b5ef-9613dd0c6168","StudyDesign_1"
